Why the Hinge Health IPO is so important for digital health
Christina Farr
6 min read
A few thoughts...
Why is longevity suddenly so hot?
Christina Farr
9 min read
Between Function Health, Lifeforce and Superpower, this space is on fire
Is health-tech entering its ‘influencer’ era?
Christina Farr
7 min read
And what are the pros and cons?
Distribution advantage: Are influencers the new moat in healthcare? with Headline VC's Georgina McMillan
Christina Farr and Luba Greenwood sit down with Headline VC’s Georgina McMillan on how celebrity and influencer endorsements move healthcare and longevity — where they build awareness, where they spread misinformation, and what an authentic, evidence-backed partnership looks like.
4 questions on President Trump and IVF
Christina Farr
4 min read
I caught up with Conceivable Life Sciences’ Joshua Abram to understand the political landscape and its impact on reproductive health
Care delivery in all 50 states? No longer as common as it used to be
Christina Farr
4 min read
Some digital health companies are getting more targeted with their approach
Let's talk about men's health: hormones, longevity, and cultural shifts, with Hone CEO Saad Alam
In this episode of Second Opinion, Christina Farr and Luba Greenwood discuss men's health with Saad Alam, co-founder and CEO of Hone Health.
Dr. Dean Ornish proved heart disease Is reversible. Now he's doing it with Alzheimer's
What Dr. Dean Ornish is showing the establishment about disease reversal
There’s a new game in town for D2C health business models
Christina Farr
7 min read
And it’s rapidly evolving in real time!
Why healthcare needs more rule breakers with Jonathan Bush, CEO of Zus Health
Luba Greenwood and Ash Zenooz interview Jonathan Bush. Jonathan is the CEO of a16z-backed Zus Health, Executive Chairman of Firefly Health and a co-founder of Athena Health.
The $1M patient keeping employers up at night w/ Lantern CEO John Zutter & Matt Harmon
In this episode of Second Opinion, Christina Farr is joined by John Zutter, CEO of Lantern, and Matt Harmon, a long time benefits executive who's worked at fortune 100 companies to discuss the rising costs of healthcare, focusing on how large employers are addressing the financial impacts of tre
How are employers going to pay for cell and gene therapies?
Christina Farr
6 min read
Let’s get real about the alliance between U.S. health care and employment